From BPI to ISPE Boston Product Show: Recapping our Recent Tradeshows
Following our attendance of ISPE Boston, BPI, and the mRNA Process Development & CMC Summit, we discuss our team's major takeaways from the events.
Throughout the months of September and October, we were excited to get to send members of our team to three trade shows throughout Massachusetts: BPI, the mRNA Process Development & CMC Summit, and ISPE Boston. Alongside our parent company Getinge, we were able to talk to attendees about the exciting projects we have in the pipeline, as well as the innovative & robust product portfolio we already have available.
After attending these insightful shows, we asked the team what their biggest takeaways were, from new and emerging trends to innovative technologies and more. Here are the main topics they discussed.
The Continued Increase in Single-Use Technologies in Bioprocessing
The bioprocessing industry has seen a substantial increase in the adoption of single-use technologies (SUTs), such as disposable bioreactors, bags, and tubing assemblies, which are quickly replacing traditional reusable stainless-steel equipment. This shift is driven by the significant operational and financial benefits of SUTs, including reduced risk of cross-contamination, and faster changeover times, and the elimination of the need for costly, time-consuming cleaning and sterilization procedures.
Single-use systems require a lower initial capital investment for new facilities, offer greater flexibility and scalability for multi-product and personalized medicine manufacturing, and can lead to reduced water and energy consumption. For more information on single-use technologies, visit our article “What is Single-Use Manufacturing”.
A Developing Interest in Continuous Bioprocessing
As we covered in our recent article “Continuous vs. Batch Processing for Biopharma Manufacturing”, although batch processing has historically been the more predominant method in bioprocessing, there is a growing industry shift toward continuous processing (CP). This interest is heavily attributed to CP's capacity for higher productivity in smaller equipment, which is particularly well-suited for high-volume pharmaceuticals like certain monoclonal antibodies (mAbs) and bispecifics.
Additionally, CP can significantly reduce a process's manufacturing footprint and its associated capital and operating costs by achieving higher throughput in a more integrated system. The increasing process intensification and the simultaneous rise of single-use technologies are further enabling the industry to overcome traditional challenges and accelerate the adoption of this more efficient manufacturing paradigm.
mRNA and Cell & Gene Therapies
While mRNA and Cell & Gene Therapies (CGT) have been key topics in the bioprocessing sphere for several years, recent industry events underscore their transformation from novel concepts to foundational pillars of modern medicine. This sustained focus is driven by their unparalleled ability to treat previously intractable diseases, creating entirely new therapeutic modalities.
More than just offering new cures, the unique manufacturing and quality challenges of these therapies are directly fueling innovation in bioprocessing. The advancements catalyzed by CGT and mRNA not only provide new avenues for treatment but are also pushing the boundaries of biomanufacturing, setting new standards for speed, agility, and precision across the entire biopharma industry.
Weren’t Able to Connect at These Events?
If you weren’t able to make it to any of these events, we would still love to connect! Our expert team can be reached at info@hp-ne.com, or you can reach out at our contact us page. Additionally, you can explore all of the products we were able to showcase at these events on our website, which includes our full product portfolio.
Share article
About HPNE
As the industry needs grow, High Purity New England, Inc. continues to supply the biopharmaceutical industry with a range of innovative products, from drug discovery and development to fill-finish, including their flagship product, custom single-use assemblies, as well as pumps, sensors, bioreactor systems, storage and handling solutions and other single-use solutions. Along with their own manufactured products for the global market, they are also a distributor for more than 18 brands in North America.
